Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB

Laboratory Investigation

Volumn 87, Issue 8, 2007, Pages 767-779

  Aoki, Mikiko ^a   Nabeshima, Kazuki ^a,b   Koga, Kaori ^a   Hamasaki, Makoto ^a   Suzumiya, Junji ^a   Tamura, Kazuo ^a   Iwasaki, Hiroshi ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Imatinib mesylate; Invasion; Malignant peripheral nerve sheath tumor (MPNST); Metastasis; PDGF BB; PDGFR

Indexed keywords

EPIDERMAL GROWTH FACTOR; HERBIMYCIN A; IMATINIB; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CELL INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME REPRESSION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

ADULT; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NERVE SHEATH NEOPLASMS; PHOSPHORYLATION; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, GROWTH FACTOR; RNA, MESSENGER;

EID: 34447576577     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700591     Document Type: Article

References (46)

1. Lewis JJ, Brennan MF. Soft tissue sarcomas. Curr Probl Surg 1996;33:817-872.
2. Scheithauer BW. Malignant peripheral nerve sheath tumor (MPNST). Tumor of the peripheral nervous system. Atlas of Tumor Pathology, third series. Armed Forces Institute of Pathology: Washington, DC, 1999.
3. Woodruff JM. Pathology of major peripheral nerve sheath tumors. Soft Tissue Tumors (International Academy of Pathology Monograph). Williams and Wilkins: Baltimore, 1996.
4. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57:2006-2021.
5. Wong WW, Hirose T, Scheithauer BW, et al. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998;42:351-360.
6. Wanebo JE, Malik JM, VandenBerg SR, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 28 cases. Cancer 1993;71:1247-1253.
7. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006;107:1065-1074.
8. Davis JB, Stroobant P. Platelet-derived growth factors and fibroblast growth factors are mitogens for rat Schwann cells. J Cell Biol 1990;110:1353-1360.
9. Eccleston PA, Funa K, Heldin CH. Expression of platelet-derived growth factor (PDGF) and PDGF alpha- and beta-receptors in the peripheral nervous system: an analysis of sciatic nerve and dorsal root ganglia. Dev Biol 1993;155:459-470.
10. Ridley AJ, Davis JB, Stroobant P, et al. Transforming growth factorsbeta 1 and beta 2 are mitogens for rat Schwann cells. J Cell Biol 1989;109:3419-3424.
11. Krasnoselsky A, Massay MJ, DeFrances MC, et al. Hepatocyte growth factor is a mitogen for Schwann cells and is present in neurofibromas. J Neurosci 1994;14:7284-7290.
12. Ratner N, Lieberman MA, Riccardi VM, et al. Mitogen accumulation in von Recklinghausen neurofibromatosis. Ann Neurol 1990;27:298-303.
13. Badache A, De Vries GH. Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J Cell Physiol 1998;177:334-342.
14. Watanabe T, Oda Y, Tamiya S, et al. Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components. J Clin Pathol 2001;54:631-636.
15. Dang I, DeVries GH. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to plateletderived growth factor-BB. J Neurosci Res 2005;79:318-328.
16. Su W, Gutmann DH, Perry A, et al. CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia 2004;45:297-306.
17. Aoki M, Nabeshima K, Nishio J, et al. Establishment of three malignant peripheral nerve sheath tumor cell lines, FU-SFT8611, 8710 and 9817: conventional and molecular cytogenetic characterization. Int J Oncol 2006;29:1421-1428.
18. Shulby SA, Dolloff NG, Stearns ME, et al. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 2004;64:4693-4698.
19. ImageJ: Image processing and analysis in Java. http://rsb.info.nih.gov/ ij/.
20. Sihto H, Franssila K, Tanner M, et al. Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours. Scand J Gastroenterol 2006;41:805-811.
21. Stoker M, Gherardi E. Regulation of cell movement: the motogenic cytokines. Biochim Biophys Acta 1991;1072:81-102.
22. Nabeshima K, Inoue T, Kataoka H, et al. Cohort migration of cancer cells. Connective Tissue 1997;29:199-212.
23. Heldin CH, Westermark B. Growth factors: mechanism of action and relation to oncogenes. Cell 1984;37:9-20.
24. Holtkamp N, Mautner VF, Friedrich RE, et al. Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol (Berlin) 2004;107:159-168.
25. DeClue JE, Heffelfinger S, Benvenuto G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000;105:1233-1241.
26. Su W, Sin M, Darrow A, et al. Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression. Glia 2003;42:350-358.
27. Hart CE, Forstrom JW, Kelly JD, et al. Two classes of PDGF receptor recognize different isoforms of PDGF. Science 1988;240:1529-1531.
28. Heldin CH, Ostman A, Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998;1378:F79-F113.
29. Li X, Ponten A, Aase K, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000;2:302-309.
30. Bergsten E, Uutela M, Li X, et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001;3:512-516.
31. Li X, Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 2003;14:91-98.
32. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
33. Santini F, Beaven MA. Nonselective actions of herbimycin A. Immunol Today 1993;14:369-370.
34. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-693.
35. Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
36. Heinrich MC, Blanke CD, Druker BJ, et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-1703.
37. Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005;23:982-989.
38. Mace J, Sybil Biermann J, Sondak V, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-2379.
39. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24:1195-1203.
40. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-873.
41. Shimizu A, O'Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999;59:3719-3723.
42. Aoki M, Nabeshima K, Nishio J, et al. Establishment of three malignant peripheral nerve sheath tumor cell lines, FU-SFT8611, 8710 and 9817: conventional and molecular cytogenetic characterization. Int J Oncol 2006;29:1421-1428.
43. Mertens F, Rydholm A, Bauer HF, et al. Cytogenetic findings in malignant peripheral nerve sheath tumors. Int J Cancer 1995;61:793-798.
44. Schmidt H, Taubert H, Wurl P, et al. Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 2001;128:14-23.
45. Holtkamp N, Okuducu AF, Mucha J, et al. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis 2006;27:664-671.
46. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.